IL23A and psoriasis: This might provide a rationale for potential therapeutic utility in T1D of more potent inhibitors of the IL-23 pathway, in current or planned use in psoriasis and inflammatory bowel disease, such as guselkumab, risankizumab, or TYK2 inhibition [31].